CN103181912A - Bexarotene soft capsules and preparation method thereof - Google Patents
Bexarotene soft capsules and preparation method thereof Download PDFInfo
- Publication number
- CN103181912A CN103181912A CN2011104595633A CN201110459563A CN103181912A CN 103181912 A CN103181912 A CN 103181912A CN 2011104595633 A CN2011104595633 A CN 2011104595633A CN 201110459563 A CN201110459563 A CN 201110459563A CN 103181912 A CN103181912 A CN 103181912A
- Authority
- CN
- China
- Prior art keywords
- bexarotene
- soft capsule
- preparation
- polysorbate
- soft capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229960002938 bexarotene Drugs 0.000 title claims abstract description 42
- 239000007901 soft capsule Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 229920003081 Povidone K 30 Polymers 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000003292 glue Substances 0.000 claims description 11
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 10
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 9
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 7
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 239000004408 titanium dioxide Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 235000019658 bitter taste Nutrition 0.000 abstract description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 abstract 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 abstract 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 abstract 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 abstract 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 201000005962 mycosis fungoides Diseases 0.000 abstract 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 13
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 13
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical class C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses bexarotene soft capsules for treating cutaneous T-cell lymphoma and a preparation method thereof. The bexarotene soft capsules consist of bexarotene, polyethylene glycol 400, polysorbate 80, povidone K30 and butylated hydroxyanisole. The soft capsules can cover up bitterness of drug and discomfortable odor, make up the defects of other solid preparations and improve drug stability. Application of the single bexarotene soft capsules improves effectiveness, safety and medication compliance of clinical medication and greatly reduces toxic or side effects of combined medication.
Description
Technical field
The invention belongs to medical technical field, more particularly, relate to a kind of skin T-cell lymphoma bexarotene soft capsule and preparation method thereof for the treatment of.
Background technology
Bexarotene crude drug chemical name: 4-[1-(5,6,7,8-tetrahydrochysene-3,5,5,8,8-pentamethyl-2-naphthyl) vinyl] benzoic acid, be an off-white color, little yellow crystal, water insoluble, be slightly soluble in vegetable oil, ethanol.
Bexarotene is a kind of novel synthetic retinoic acid analog, is used for the treatment of intractable skin T-cell lymphoma, and this disease is relatively easily cured in early days, and As time goes on, grade of malignancy constantly increases, and cures difficulty and also strengthens relatively.Skin T-cell lymphoma is increasing year by year at the sickness rate of China, according to this sick particularity, there are shortcomings such as toxic and side effects is big, curative effect is low and the persistent period is short, therapeutic regimen is complicated, medical expense costliness in the current simple direct radiotherapy of skin or the modularization therapy of whole body of adopting.
The bexarotene oral soft capsule to the patient provide a kind of new, easily, only take the method for single pharmaceutical treatment intractable skin T-cell lymphoma.The bexarotene oral soft capsule is with its bioavailability height, sealingly secure, and content is accurate, and is aesthetic in appearance etc., and characteristics are better than other peroral dosage forms, and have lowered the toxic and side effects of drug combination greatly, have increased the safety of medication.
Summary of the invention
The object of the present invention is to provide a kind of skin T-cell lymphoma treating medicine bexarotene soft capsule and preparation method thereof.
The bexarotene soft capsule of the present invention's preparation is the finely dispersed suspension of a content, and having major advantage has: soft capsule smooth in appearance, content are uniformly dispersed, are easy to absorb.Stable preparation process need not specific condition and equipment, is easy to suitability for industrialized production.According to the requirement of medicine stability guideline, carried out influence factor's test, accelerated test and long term test, the result shows that the bexarotene soft capsule quality is stable.
Technology contents of the present invention passes through following technical proposal:
The bexarotene soft capsule is characterized in that, is made up of bexarotene, PEG400, Polysorbate, polyvidone, butylated hydroxyarisol.Each component preferred content of wherein said per unit dosage is:
PEG400 of the present invention is diluent.Polysorbate is polysorbate 20, polysorbate 60, polyoxyethylene sorbitan monoleate, as emulsifying agent, and preferred polyoxyethylene sorbitan monoleate.
Described polyvidone is that 30 POVIDONE K 30 BP/USP 30 is as binding agent.
Butylated hydroxyarisol is as antioxidant.
The preparation method of bexarotene soft capsule of the present invention comprises:
(1) changes glue
Capsule skin component: gelatin-glycerol-sorbitol-water-titanium dioxide (80: 24: 20: 80: 1)
Change glue process: will be heated to 85 ℃ in a certain proportion of putting into of water glue jar earlier, then gelatin, glycerol, sorbitol, titanium dioxide are heated to preference temperature in the input glue jar in proportion, fully stirred 30～60 minutes, material is dissolved fully, get rid of bubble through evacuation, namely.
(2) preparation
Bexarotene is handled through jet mill, standby.Press recipe quantity, accurately take by weighing bexarotene, 30 POVIDONE K 30 BP/USP 30, polyoxyethylene sorbitan monoleate, butylated hydroxyarisol, the adding PEG400 is an amount of, grinds and stirs, and namely gets this product content suspension, and is standby.This suspension is transferred in the hopper of pellet processing machine, bucket temperature control temperature is 60～65 ℃, suppresses soft capsule, the curing of deoiling, and washing with alcohol, 50～60 ℃ of dryings, packing is namely.Loading amount is about 546mg, and every contains bexarotene (C
24H
28O
2) 75mg.
The major advantage of bexarotene soft capsule of the present invention has:
1. patient's compliance of taking medicine is good: soft capsule can be covered bitterness and the uncomfortable stink of medicine; Can have all right lettering of shades of colour as a means of difference, neat and artistic, be easy to take, easy to carry, welcome by patient.2. remedy the deficiency of other solid dosage forms: principal agent is water insoluble, is not easy to absorb in digestive tract, it can be dissolved in the suitable adjuvant, makes soft capsule again, in order to absorption.3. bioavailability height: soft capsule disperses fast at gastric, stripping is fast, and good absorbing is generally proved effective than tablet soon.4. improve medicine stability: prevent that medicine is subjected to the effect of oxygen and light in dampness, the air, to improve its stability.
Bexarotene soft capsule of the present invention is mainly used in treating skin T-cell lymphoma.Skin T-cell lymphoma is the skin lymphocyte malignant tumor that skin injury is arranged.The T-cell lymphoma uses the electric shock X-radiation treatment on associating whole body anti-tumor chemotherapeutic medicine, general immunosuppressant, PUVA or surface usually.But it is short to exist not high and reaction period of effective percentage, medical expense costliness, shortcoming such as toxic and side effects is big.The bexarotene oral soft capsule to the patient provide a kind of new, easily, only take the method for single pharmaceutical treatment intractable skin T-cell lymphoma.The clinical research result shows that the bexarotene soft capsule is safe to intractable skin T-cell lymphoma treating, good toleration is arranged usually, put aside low in vivo, though there is untoward reaction to take place, but untoward reaction symptom general after the drug withdrawal can be recovered, and can effectively treat skin T-cell lymphoma late period, intractable.
The bexarotene soft capsule is effective in cure to two kinds of reactionless early stage skin T-cell lymphoma patients 67% that maybe can not tolerate of method, and skin T-cell lymphoma patient has 55% curative effect to late period.Use single bexarotene soft capsule to improve the effectiveness of clinical application, safety and medication compliance have lowered the toxic and side effects of drug combination greatly.
Further specify good effect of the present invention below in conjunction with dissolution and stability test:
1. dissolution determination
Test method: get this product, according to dissolution determination method (Chinese Pharmacopoeia version appendix in 2000 XC first method), operation in accordance with the law, result of the test sees Table 1.
45 minutes dissolution Q% of table 1. bexarotene soft capsule
| Soft capsule number | 1 | 2 | 3 | 4 | 5 | 6 | Average Q% | RSD％ |
| 040712 | 84.25 | 85.95 | 86.37 | 84.46 | 83.40 | 82.77 | 84.53 | 1.66 |
2. stability experiment
Investigated the influence of factors such as strong illumination, heat (40 ℃, 60 ℃), high humidity to bexarotene soft capsule stability.The result shows: the every index of bexarotene soft capsule is not seen significant change, related substance, dissolution, assay, with 0 day data and collection of illustrative plates relatively, basically identical, result of the test sees Table 2, table 3.The having good stability of formulation and technology of said preparation is described, proved the reasonability of this product formulation and technology.
Table 2. bexarotene soft capsule influence factor result of the test
Table 3 bexarotene soft capsule high humidity test specimen weightening finish result
| The grain number | 0 day (g) | 10 days (g) | Gain in weight (g) | Gain in weight (%) |
| 10 | 5.2871 | 5.3146 | 0.0275 | 0.52 |
The specific embodiment
The present invention is described further below in conjunction with embodiment.Embodiment can not be used for limiting the present invention with this only to explanation of the present invention.
Embodiment 1
Preparation method:
(1) change glue:
Capsule skin component: gelatin-glycerol-sorbitol-water-titanium dioxide (80: 24: 20: 80: 1);
Change glue process: will be heated to 85 ℃ in a certain proportion of putting into of water glue jar earlier, then gelatin, glycerol, sorbitol, titanium dioxide are heated to preference temperature in the input glue jar in proportion, fully stirred 30～60 minutes, material is dissolved fully, get rid of bubble through evacuation, namely.
(2) preparation:
Bexarotene is handled through jet mill, standby.Press recipe quantity, accurately take by weighing bexarotene, 30 POVIDONE K 30 BP/USP 30, polyoxyethylene sorbitan monoleate, butylated hydroxyarisol, the adding PEG400 is an amount of, grinds and stirs, and namely gets this product content suspension, and is standby.This suspension is transferred in the hopper of pellet processing machine, bucket temperature control temperature is 60～65 ℃, suppresses soft capsule, the curing of deoiling, and washing with alcohol, 50～60 ℃ of dryings, packing is namely.Loading amount is about 428.3mg, and every contains bexarotene (C
24H
28O
2) 75mg.
Embodiment 2
Preparation method is with embodiment 1.
Embodiment 3
Preparation method is with embodiment 1.
Embodiment 4
Preparation method is with embodiment 1.
Embodiment 5
Preparation method is with embodiment 1.
Embodiment 6
Preparation method is with embodiment 1.
Claims (5)
1. a bexarotene soft capsule is characterized in that, is made up of bexarotene, PEG400, Polysorbate, polyvidone, butylated hydroxyarisol; Wherein said Polysorbate is polysorbate 20, polysorbate 60, polyoxyethylene sorbitan monoleate.
2. bexarotene soft capsule as claimed in claim 1, wherein said each preferred ingredients of per unit dosage is: bexarotene, PEG400, polyoxyethylene sorbitan monoleate, 30 POVIDONE K 30 BP/USP 30, butylated hydroxyarisol.
3. bexarotene soft capsule as claimed in claim 1 or 2, wherein said each constituent content of per unit dosage is:
4. bexarotene soft capsule as claimed in claim 3, wherein said each constituent content of per unit dosage is:
5. the preparation method as each described bexarotene soft capsule of claim 1-4 is characterized in that comprising the steps:
(1) change glue: capsule skin component is according to gelatin: glycerol: sorbitol: water: titanium dioxide is 80: 24: 20: 80: 1 ratio, earlier will be heated to 85 ℃ in a certain proportion of putting into of water glue jar, then gelatin, glycerol, sorbitol, titanium dioxide are heated to preference temperature in the input glue jar in proportion, fully stirred 30～60 minutes, material is dissolved fully, get rid of bubble through evacuation, namely;
(2) preparation: press recipe quantity, accurately take by weighing bexarotene, 30 POVIDONE K 30 BP/USP 30, polyoxyethylene sorbitan monoleate, butylated hydroxyarisol, the adding PEG400 is an amount of, grinds and stirs, and namely gets this product content suspension, and is standby; Suspension is transferred in the hopper of pellet processing machine, bucket temperature control temperature is 60～65 ℃, suppresses soft capsule, the curing of deoiling, and washing with alcohol, 50～60 ℃ of dryings, packing is namely.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104595633A CN103181912A (en) | 2011-12-31 | 2011-12-31 | Bexarotene soft capsules and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104595633A CN103181912A (en) | 2011-12-31 | 2011-12-31 | Bexarotene soft capsules and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103181912A true CN103181912A (en) | 2013-07-03 |
Family
ID=48673529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104595633A Pending CN103181912A (en) | 2011-12-31 | 2011-12-31 | Bexarotene soft capsules and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103181912A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018149364A1 (en) * | 2017-02-16 | 2018-08-23 | 人福普克药业（武汉）有限公司 | Bexarotene soft capsule and preparation method thereof |
| CN110455932A (en) * | 2018-05-08 | 2019-11-15 | 人福普克药业（武汉）有限公司 | A method of the measurement enzyme dissolution of Bertha Luo Ting soft capsule |
| CN112569202A (en) * | 2019-09-27 | 2021-03-30 | 人福普克药业（武汉）有限公司 | Bexarotene capsule and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883537A (en) * | 2006-06-13 | 2006-12-27 | 贵州神奇集团控股有限公司 | Compound Chinese medicinal preparation for treating hypertension and hyperlipemia and preparation method thereof |
-
2011
- 2011-12-31 CN CN2011104595633A patent/CN103181912A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883537A (en) * | 2006-06-13 | 2006-12-27 | 贵州神奇集团控股有限公司 | Compound Chinese medicinal preparation for treating hypertension and hyperlipemia and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| RAMPURNA PRASAD GULLAPALLI: "Soft Gelatin Capsules (Softgels)", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018149364A1 (en) * | 2017-02-16 | 2018-08-23 | 人福普克药业（武汉）有限公司 | Bexarotene soft capsule and preparation method thereof |
| CN108434116A (en) * | 2017-02-16 | 2018-08-24 | 人福普克药业（武汉）有限公司 | Bei Saluoting soft capsules and preparation method thereof |
| US20190038566A1 (en) * | 2017-02-16 | 2019-02-07 | Humanwell PuraCap Pharamaceuticals (Wuhan) Co., Ltd. | Bexarotene softgel capsule and preparation method thereof |
| CN108434116B (en) * | 2017-02-16 | 2021-05-11 | 人福普克药业（武汉）有限公司 | Bexarotene soft capsule and preparation method thereof |
| US11331275B2 (en) | 2017-02-16 | 2022-05-17 | Humanwell Puracap Pharmaceuticals (Wuhan) Co., Ltd | Bexarotene softgel capsule and preparation method thereof |
| CN110455932A (en) * | 2018-05-08 | 2019-11-15 | 人福普克药业（武汉）有限公司 | A method of the measurement enzyme dissolution of Bertha Luo Ting soft capsule |
| CN112569202A (en) * | 2019-09-27 | 2021-03-30 | 人福普克药业（武汉）有限公司 | Bexarotene capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102145062A (en) | Active extracts of rosa roxburghii tratt fruit, and preparation method, detection method and application thereof | |
| CN103181912A (en) | Bexarotene soft capsules and preparation method thereof | |
| CN101671319B (en) | Taxus nontoxic extract process | |
| CN101062029B (en) | Application of wogonin in preparation of medicine for treating gastric cancer | |
| CN113575958A (en) | Health-care composition and capsule for improving immunity function and preparation method thereof | |
| CN107041895A (en) | Antrodia camphorata composition for inhibiting renal cancer cell proliferation and improving renal function | |
| CN1919339A (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| CN101524353B (en) | Oral anti-allergy compound pharmaceutical composition | |
| CN104000876A (en) | Composition of mangnolia officinalis and gingerol and application thereof | |
| CN104327068B (en) | Anticancer analgesic selenium-containing compound and preparation method and application thereof | |
| CN105434446B (en) | Triptolide traditional Chinese medicine compound film coating agent and preparation method and application thereof | |
| CN103710264B (en) | A kind of wall-breaking auxiliary additive of Ganoderma lucidum spore | |
| CN105520913B (en) | Pellet containing saxagliptin, application and preparation method thereof | |
| CN102232957B (en) | Use of 3-acetoxyl-8, 24-lanostadiene-21-acid in preparing medicines for preventing or treating liver cancer or breast cancer | |
| WO2011095095A1 (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN101653503A (en) | Gonglao quhuo capsules for treating various inflammation, heat-clearing and detoxifying and preparation method thereof | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN105267793B (en) | A kind of new application of Chinese medicine composition | |
| CN105796498A (en) | Powder coated folic acid and preparation method thereof | |
| CN104257626A (en) | A kind of secnidazole soft capsule and preparation method thereof | |
| CN113244208B (en) | Application of HPA in the preparation of drugs for the treatment of non-alcoholic fatty liver disease | |
| CN101559063B (en) | External medicament for curing herpes zoster and preparation method thereof | |
| CN104546793A (en) | Blood-sugar-reducing coprinus comatus capsule preparation and preparation method thereof | |
| CN102626426B (en) | Anti-tumor compound poria cocos preparation and preparation method thereof | |
| CN100336526C (en) | Medicine composition for treating diabetes and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130703 |